Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted

• Mucinex® (Drug), also known as guaifenesin: Mucinex® 600 mg ER bi-layer tablets

Primary outcomes

• Maximum Observed Plasma Concentration (Cmax) of Guaifenesin [0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)]: Maximum measured analyte concentration over the sampling period.
• Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin [0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)]: The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.

Secondary outcomes

• Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin [0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)]: Time of the maximum measured analyte concentration over the sampling period.
• Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin [0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)]: The area under the analyte concentration versus time curve from time zero to infinity. AUCinf = AUCt + Cp/Kel, where Cp is the predicted analyte concentration at the time of the last measurable analyte concentration.
• Terminal Elimination Rate Constant (Kel) of Guaifenesin [0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)]: Elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least-squares regression of log (concentration) versus time.
• Terminal Elimination Half-life (T½) of Guaifenesin [0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)]: Terminal elimination half-life, calculated from the equation: thalf = In(2)/Kel.
• Relative Bioavailability (RF) of Guaifenesin [0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)]: Relative bioavailability for each formulation will be defined as: (AUC0-inf Fasting ÷ AUC0-inf Fed) x (Fed dose ÷ Fasting dose)
• Number of Adverse Events(AEs) Experienced by Participants [Up to period 2 (8.3 days/200 hours)]: Intensity determination Mild=AE does not limit usual activities;subject may experience slight discomfort Moderate=AE results in some limitation of usual activities;subject may experience significant discomfort Severe=AE results in an inability to carry out usual activities;subject may experience intolerable discomfort or pain Unassessable/Unclassifiable=Insufficient information to be able to make an assessment Conditional/Unclassified=Insufficient information to make an assessment at present(causality is conditional on additional information) Unrelated=No possibility that the AE was caused by study drug Unlikely=Slight but remote chance that the AE was caused by study drug but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug Probable=Most likely that the AE was caused by study drug Certain=The AE was definitely caused by study drug

Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers

Inclusion Criteria:

1. Informed consent was obtained (i.e. be informed of the nature of the study and given written consent prior to any study procedure). Able to read, understand, and sign the informed consent, after the nature of the study had been explained.
2. Age: 18 to 55 years of age, inclusive.
3. Sex: male or female.
4. Status: Healthy subjects.
5. BMI: ≥18.0 and ≤28.0 kg/m2.
6. No clinically significant findings in vital signs measurements at screening.
7. No clinically significant abnormal laboratory values at screening.
8. No clinically significant findings from a 12-lead electrocardiogram (ECG) at screening.
9. Had no significant diseases or clinically relevant medical condition in the opinion of the Investigator
10. Males who participated in this study were willing to:

    * remain abstinent \[not engage in sexual intercourse\] from the start of drug administration until 90 days after the end of the study or
    * used (or their partner used, as applicable) two effective methods of birth control \[condom, diaphragm, cervical cap, vaginal sponge, spermicide, IUD, tubal ligation, vasectomy, or hormonal contraceptives\] from the start of drug administration until 90 days after the end of the study.

    Females who participated in this study were:
    * unable to have children (e.g., post-menopausal, hysterectomy);
    * willing to remain abstinent \[not engage in sexual intercourse\] from 21 days prior to drug administration until 30 days after the end of the study; or
    * willing to use two effective methods of birth control \[condom, diaphragm, cervical cap, vaginal sponge, spermicide, non-hormonal Intrauterine Device (IUD) (in place for 3 months), tubal ligation, partner has vasectomy, hormonal contraceptives for 3 months prior to drug administration\] from 30 days prior to drug administration until 30 days after the end of the study.
11. Had no clinically significant findings from a physical examination.

Exclusion Criteria:

1. Employee of Pharma Medica Research Inc. (PMRI) or Reckitt Benckiser.
2. Partner or first-degree relative of any Investigator at PMRI.
3. Known history or presence of any clinically significant medical condition.
4. Known or suspected carcinoma.
5. Presence of hepatic or renal dysfunction.
6. Presence of clinically significant gastrointestinal disease or history of malabsorption within the year preceding the study.
7. Known history or presence of galactose or fructose intolerance, sucrase-isomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome.
8. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
9. History of drug or alcohol or medicinal product addiction requiring treatment within the two years preceding the study or excessive alcohol consumption (more than 10 units per week)

   Note: one unit is defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of spirits.
10. Positive test result for serum Human Chorionic Gonadotropin (hCG) consistent with pregnancy (females only), HIV, Hepatitis B surface antigen or Hepatitis C antibody.
11. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and benzodiazepines) or urine cotinine.
12. Difficulty fasting or consuming standard meals.
13. Females who were lactating.
14. Did not tolerate venipuncture.
15. Use of tobacco or nicotine-containing products within 12 months prior to drug administration.
16. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
17. Donation or loss of whole blood (including clinical trials):

    * ≥50 ml and ≤499 ml within 30 days prior to drug administration
    * ≥500 ml within 56 days prior to drug administration
18. Females who had started taking hormonal contraceptives or had changed their method or brand of hormonal birth control within 3 months prior to drug administration.
19. Had a tattoo or body piercing within 30 days prior to drug administration.
20. Use of drugs of the monoamine oxidase inhibitor (MAOI) class within 30 days prior to drug administration.
21. Known history or presence of hypersensitivity, intolerance or idiosyncratic reaction to guaifenesin or any other drug substances with similar activity.
22. Previously enrolled in this study.
23. Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
24. Unable in the opinion of the Investigator to comply fully with the study requirements.

Participant flow

Outcome results

• Maximum Observed Plasma Concentration (Cmax) of Guaifenesin (Primary), Mean, ng/ml: Treatment A: Mucinex® 600 mg (Fast) 1066.11 +/- 429.91; Treatment B: Mucinex® 600 mg (Fed) 1117.31 +/- 424.82
• Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin (Primary), Mean, ng·h/ml: Treatment A: Mucinex® 600 mg (Fast) 4052.10 +/- 1495.48; Treatment B: Mucinex® 600 mg (Fed) 4084.90 +/- 1380.20
• Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin (Secondary), Mean, h: Treatment A: Mucinex® 600 mg (Fast) 0.68 +/- 0.32; Treatment B: Mucinex® 600 mg (Fed) 3.33 +/- 1.36
• Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin (Secondary), Mean, ng·h/ml: Treatment A: Mucinex® 600 mg (Fast) 4104.47 +/- 1555.87; Treatment B: Mucinex® 600 mg (Fed) 4092.53 +/- 1382.77
• Terminal Elimination Rate Constant (Kel) of Guaifenesin (Secondary), Mean, 1/h: Treatment A: Mucinex® 600 mg (Fast) 0.3862 +/- 0.1717; Treatment B: Mucinex® 600 mg (Fed) 0.6788 +/- 0.1343
• Terminal Elimination Half-life (T½) of Guaifenesin (Secondary), Mean, h: Treatment A: Mucinex® 600 mg (Fast) 2.46 +/- 2.62; Treatment B: Mucinex® 600 mg (Fed) 1.07 +/- 0.29
• Relative Bioavailability (RF) of Guaifenesin (Secondary), Mean, Percent bioavailability: All Study Participants 1.0081 +/- 0.1655
• Number of Adverse Events(AEs) Experienced by Participants (Secondary), Number, Events: Treatment A: Mucinex® 600 mg (Fast) 11; Treatment B: Mucinex® 600 mg (Fed) 14

Adverse events

Time frame: Up to 8.3 days/ (200 hours)

Other adverse events by term